Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy

Author(s): Angelos G. Rigopoulos, Hubert Seggewiss

Journal Name: Current Cardiology Reviews

Volume 12 , Issue 4 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Hypertrophic obstructive cardiomyopathy is the most common genetic cardiac disease and is generally characterised by asymmetric septal hypertrophy and intraventricular obstruction. Patients with severe obstruction and significant symptoms that persist despite optimal medical treatment are candidates for an invasive septal reduction therapy. Twenty years after its introduction, percutaneous transluminal alcohol septal ablation has been increasingly preferred for septal reduction in patients with drug refractory hypertrophic obstructive cardiomyopathy. Myocardial contrast echocardiography and injection of reduced alcohol volumes have increased safety, while efficacy is comparable to the surgical alternative, septal myectomy, which has for decades been regarded as the ‘gold standard’ treatment. Data on medium- and long-term survival show improved prognosis with survival being similar to the general population. Current guidelines have supported its use by experienced operators in centres specialised in the treatment of patients with hypertrophic obstructive cardiomyopathy.

Keywords: Alcohol septal ablation, hypertrophic cardiomyopathy, hypertrophy, myocardial contrast echocardiography, septal reduction, survival.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [285 - 296]
Pages: 12
DOI: 10.2174/1573403x11666150107160344
Price: $65

Article Metrics

PDF: 29